Drugs / Furuitinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06717880 | Jul 2023 → Jul 2025 overdue | cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Furuitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06717880 ↗ |
| Route | Oral | “IBI363 Q2W or Q3W IV，Furuitinib po” NCT06717880 ↗ |